Snapshot from Jul 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Scribe Therapeutics IPO Pricing
Business initial public offering

Scribe Therapeutics IPO Pricing

Analysis based on 6 articles · First reported Jul 24, 2026 · Last updated Jul 24, 2026

Sentiment
40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The IPO provides Scribe Therapeutics Inc. with capital to advance its CRISPR-based therapies, potentially boosting investor interest in the gene-editing sector. The concurrent private placement by Sanofi signals strategic partnership interest, which may positively affect Scribe's valuation and market perception.

biotechnology pharmaceuticals
Event Summary

Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in CRISPR-based genetic medicines, priced its upsized initial public offering of 8,580,000 shares at $15.00 per share, raising $128.7 million. The shares will trade on the Nasdaq under the symbol SCTX starting July 24, 2026. Concurrently, Scribe agreed to a private placement of 500,000 shares to Sanofi at the same price. The offering was underwritten by Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities. The SEC declared the registration statement effective on July 23, 2026.

Key Actions
100 Scribe Therapeutics Inc. priced upsized IPO
70 Scribe Therapeutics Inc. agreed private placement Sanofi
50 United States — United States Securities and Exchange Commission declared effective Scribe Therapeutics Inc.
30 Scribe Therapeutics Inc. granted underwriter option
Entities Involved
priv
Scribe Therapeutics Inc.
Scribe Therapeutics Inc. successfully priced its upsized IPO, raising $128.7 million, and secured a private placement from Sanofi, strengthening its financial position for clinical development.
Importance 100.0 Sentiment 60.0
stock
Sanofi
Sanofi participated in a concurrent private placement, purchasing 500,000 shares of Scribe Therapeutics Inc., indicating continued collaboration interest.
Importance 70.0 Sentiment 30.0
priv
Leerink Partners
Leerink Partners acted as a joint book-running manager for the IPO, earning underwriting fees and enhancing its reputation in biotech IPOs.
Importance 40.0 Sentiment 10.0
stock
Goldman Sachs
Goldman Sachs served as a joint book-running manager, generating underwriting revenue and reinforcing its investment banking presence.
Importance 40.0 Sentiment 10.0
priv
Guggenheim Partners
Guggenheim Securities acted as a joint book-running manager, earning fees from the IPO.
Importance 40.0 Sentiment 10.0
stock
Wells Fargo
Wells Fargo Securities participated as a joint book-running manager, generating underwriting income.
Importance 40.0 Sentiment 10.0
govactor
United States — United States Securities and Exchange Commission
The SEC declared the registration statement effective, enabling the IPO to proceed, fulfilling its regulatory role.
Importance 30.0 Sentiment 0.0
per
Jennifer Doudna
Jennifer Doudna is a co-founder of Scribe Therapeutics Inc.; her Nobel Prize association lends credibility but is not directly impacted by the IPO.
Importance 30.0 Sentiment 10.0
exch
Nasdaq
Nasdaq will list Scribe Therapeutics Inc. under the ticker SCTX, adding a new listing and earning listing fees.
Importance 20.0 Sentiment 5.0
stock
Eli Lilly and Company
Eli Lilly is mentioned as a strategic collaborator of Scribe Therapeutics Inc. but is not directly involved in the IPO event.
Importance 20.0 Sentiment 0.0
Relationships
Goldman Sachs related ↔ Guggenheim Partners
Goldman Sachs related ↔ Wells Fargo
Goldman Sachs related ↔ United States — United States Securities and Exchange Commission
Goldman Sachs related ↔ Nasdaq
Goldman Sachs related ↔ Eli Lilly and Company
Guggenheim Partners related ↔ United States — United States Securities and Exchange Commission
Wells Fargo related ↔ United States — United States Securities and Exchange Commission
United States — United States Securities and Exchange Commission related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.